Novel use of menstrual blood for monitoring glycaemic control in patients with diabetes: a proof-of-concept study

• Published in: BMJ sexual & reproductive health Vol. 48; no. 2; p. 123
• Main Authors: Naseri, Sara, Brewster, Ryan Charles Leung, Blumenthal, Paul D
• Format: Journal Article
• Language: English
• Published: England 01-04-2022
• Subjects: Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - diagnosis; Female; Glycated Hemoglobin A - analysis; Glycemic Control; Humans; Prospective Studies; reproductive health; general practice
• ISSN: 2515-2009
• DOI: 10.1136/bmjsrh-2021-201211

Glycated haemoglobin (HbA1c) is the diagnostic and prognostic standard for clinical management of diabetes mellitus (DM). Unfortunately, patient adherence to guidelines for routine testing can be poor and there are significant gender-based disparities in DM management and outcomes. Recent evidence suggests that menstrual blood may be comparable to systemic blood for monitoring of common biomarkers. The objective of the present study was to assess the concordance of HbA1c levels between menstrual and systemic blood in healthy women and women with diabetes of reproductive age.
In this prospective, observational cohort study, we enrolled healthy and diabetic (type 1 and type 2 DM) reproductive-age women (aged ≥18 and ≤45 years). Menstrual blood and venous systemic blood specimens were simultaneously obtained at time of menstruation, and analysed for HbA1c levels. Participants self-collected menstrual blood using a QPad, a novel, modified menstrual pad with an embedded dried blood spot strip.
Among 172 participants, 57.6% were healthy and 42.4% had a diagnosis of either type 1 or type 2 DM. There were no significant differences in mean HbA1c values in menstrual and systemic blood across the overall cohort or within the diabetic subgroup. Furthermore, HbA1c levels between blood sources were robustly correlated and demonstrated a significant linear relationship.
There is a strong concordance in HbA1c levels between menstrual and systemic blood. Empowered by self-collection technologies, these findings suggest that menstrual blood may serve as a reliable, non-invasive and potentially cost-effective alternative to serum for HbA1c monitoring among reproductive-age women with DM.